CROs and service providers at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
66 CROs and service providers are at ASH 2026 — 41 presentations on the program and 44 with a booth in the exhibit hall. Most represented: Sarah Cannon Research Institute (4 on the program), Parexel (4 on the program), Medscape (2 on the program). 47 of them have their own page in this guide. As of Nov 10, 2026.
Topic
Top represented
Showing 1–8 of 66 organizations
| Organization | ASH 2026 Attendance |
|---|---|
Sarah Cannon Research Institute Nashville, TN | |
Oncology research organization running cancer clinical trials in community settings for more than 30 years. | Booth Exhibiting at Booth 2316 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm Best Practice Use of Bispecific Antibodies in Non-Hodgkin Lymphoma – A Second Opinion Case Review Difficult non-Hodgkin lymphoma cases treated or considered for bispecific antibodies, with reviews of recent data, current practice, and ongoing trials. Session Fri Dec 11 2:15pm–2:35pm Oral Sat Dec 12 2:00pm–3:30pm Poster Sat Dec 12 5:30pm–7:30pm Poster Sun Dec 13 6:00pm–8:00pm Poster Sun Dec 13 6:00pm–8:00pm Poster Mon Dec 14 6:00pm–8:00pm Poster Mon Dec 14 6:00pm–8:00pm Session |
Parexel Durham, NC | |
Global contract research organization providing clinical trial, regulatory consulting and real-world evidence services to biopharma. | Booth Exhibiting at Booth 2457 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Poster Sat Dec 12 5:30pm–7:30pm Poster Sun Dec 13 6:00pm–8:00pm Oral Mon Dec 14 10:30am–12:00pm |
Medscape Newark, NJ | |
Online news, clinical reference tools and continuing medical education for oncology and hematology professionals. | Booth Exhibiting at Booth 3239 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Poster Sat Dec 12 5:30pm–7:30pm |
Analysis Group Boston, MA | |
An economic consulting firm headquartered in Boston, Massachusetts. | Poster Sat Dec 12 5:30pm–7:30pm Poster Mon Dec 14 6:00pm–8:00pm |
AE Arensia Exploratory Medicine Kyiv, Ukraine | |
Clinical research organization in Kyiv, Ukraine. | Poster Sat Dec 12 5:30pm–7:30pm |
GH Greco-Hainsworth Tennessee Oncology Centers for Research Nashville, TN | |
Oncology clinical research organization in Nashville, Tennessee. | Poster Sat Dec 12 5:30pm–7:30pm |
PeerView Institute for Medical Education New York, NY | |
Accredited continuing medical education provider producing live and online programs for clinicians, including hematology and oncology symposia. | Symposium Fri Dec 11 7:00am–10:00am Next in Line for Relapsed/Refractory Myeloma: Sequencing Strategies With T-Cell Engagers, Next-Generation CAR-T, and Innovative MOAs Sequencing relapsed myeloma treatments as next-generation CAR-T, multi-target T-cell engagers, and new drug classes arrive, plus managing their toxicity. Symposium Fri Dec 11 11:00am–2:00pm Advancing Bispecific Pathways in ALL: How Clinical Experience and New Science are Informing Off-the-Shelf Innovation Bispecific T-cell engagers in B-cell acute lymphoblastic leukemia, including gentler next-generation versions for patients unsuited to or relapsing after CAR-T. Symposium Fri Dec 11 11:00am–2:00pm Realigning Modern Care in MCL: Guidance on the Next Wave of Advances With BTK Inhibitor Options and New Targeted Strategies Mantle cell lymphoma care built on Bruton tyrosine kinase inhibitors up front, with newer kinase and Bcl-2 inhibitors or CAR-T after relapse. Symposium Fri Dec 11 3:00pm–6:00pm FAST Track to Enhanced CLL Outcomes: Finite Therapy Advances With BTK Inhibitors as New STandards for Frontline Treatment Time-limited frontline chronic lymphocytic leukemia treatment pairing Bruton tyrosine kinase and Bcl-2 inhibitors, tailored to patient goals and risk. Symposium Fri Dec 11 3:00pm–6:00pm The Rising Tide of Bispecifics in NHL: Off-the-Shelf Opportunities From Later-Line to Frontline Care Bispecific antibodies moving from late to early treatment of non-Hodgkin lymphoma, with outpatient step-up dosing and control of immune side effects. Symposium Fri Dec 11 7:00pm–10:00pm Accelerating CARs for Lymphoma: Expert Workshops on CAR-T Standards, Sequencing, and Emerging Cellular Therapy Platforms CAR-T as standard lymphoma care and what comes next, including dual-target, faster-manufactured, and in vivo versions that could widen patient access. Poster Sat Dec 12 5:30pm–7:30pm Poster Sun Dec 13 6:00pm–8:00pm Poster Mon Dec 14 6:00pm–8:00pm |
Decera Clinical Education Reston, VA | |
Accredited medical education company (Clinical Education Alliance) running clinician education programs and satellite symposia, with data and market-research services. | Booth Exhibiting at Booth 2123 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm CAR T-Cell Agent Integration in Lymphoma: A Masterclass for Real-World Implementation CAR-T for relapsed B-cell lymphomas, from patient selection and referral to managing immune and nerve toxicities, survivorship, and off-the-shelf products. Symposium Fri Dec 11 11:00am–2:00pm CLL Challenge! Interrogating the Latest Evidence on Patient Priorities and Novel Targeted Therapies Shared decision-making in chronic lymphocytic leukemia, using biomarker testing to choose among fixed-duration, continuous, and newer targeted treatments. Symposium Fri Dec 11 11:00am–2:00pm Mastering Systemic Mastocytosis: Diagnostic Criteria, Risk Stratification, and Patient-Centered Treatment Across Indolent and Advanced Disease Diagnosing systemic mastocytosis, separating indolent from advanced disease, preventing anaphylaxis, and choosing between symptom control and Kit-targeted drugs. Symposium Fri Dec 11 3:00pm–6:00pm Myeloma Challenge! Test Your Knowledge of Updated Guidelines and Evidence-Based Practice Guideline-based myeloma care from smoldering disease to late relapse, including three- or four-drug regimens, residual disease testing, and newer immunotherapies. Symposium Fri Dec 11 3:00pm–6:00pm Optimizing Integration of BsAb-Based Therapies for FL and DLBCL: Expert Perspectives on New Standards and Future Directions How bispecific antibodies for follicular and diffuse large B-cell lymphoma differ in structure, dosing, and safety, and how to sequence them in community care. |
Find buyers from CROs and service providers
Tell us what you sell and we’ll find the people at these CROs and service providers most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse ASH 2026 by
Organization type
Topic
- Leukemias, MDS & MPN 754
- Lymphoma & CLL 656
- Myeloma & Amyloidosis 374
- Bispecifics, ADCs & Targeted Drugs 510
- Transplant, Cell & Gene Therapy 521
- Sickle Cell, Anemia & Red Cell Disorders 359
- Bleeding, Clotting & Platelets 318
- Stem Cells & Blood Biology 671
- AI, Genomics & Data 204
- Clinical Practice & Access to Care 986
Exhibit hall
Program
Everyone
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction